Impact of blood glucose control on clinical outcomes in type 2 diabetes patients hospitalized with COVID-19 infection
Elena Chertok Shacham, Nimra Maman, Avraham Ishay
Diabetes and Vascular Disease Research, doi:10.1177/14791641241288390
Our study evaluates the interconnection between diabetes treatment in the community setting and diabetes treatment regimens in these patients during hospitalization.
Methods: The patients were divided into four groups according to blood glucose level during hospitalization. Group 1 included patients with an average blood glucose ≤140 mg/dl, Group 2 included patients with an average blood glucose level between 140 and 180 mg/dl, Group 3 included patients whose blood glucose level was between 180 and 250 mg/dl, and Group 4 included patients with average blood glucose >250 mg/dl. In all subjects, we assessed preadmission diabetes treatment and prior diagnoses of major comorbidities (atherosclerotic cardiovascular disease, congestive heart failure, chronic renal disease, chronic pulmonary diseases, and dementia. Results: Significant predictors of mortality were the severity of COVID-19 (OR 62, CI 95%; 18-235, p < .000), acute renal failure (OR 3.2, CI 95% -1.26-8.2; p = .015), and a diagnosis of congestive heart failure before hospitalization (OR 2.6; CI 95% 1.14-6.8; p = .024). Lower preadmission HbA1c levels, insulin treatment in the hospital, SGLT-2 treatment before, and absence of acute renal failure are significant predictors of good glycemic control during hospitalization. Conclusions: In patients with type 2 diabetes hospitalized with COVID-19, poor long-term glycemic control is associated with the level of hyperglycemia during hospitalization.
Appendix
List of abbréviations
References
Bramante, Huling, Tignanelli, Randomized trial of metformin, ivermectin, and fluvoxamine for covid-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Chander, Deepak, Kumari, Glycemic control in critically ill COVID-19 patients: systematic review and meta-analysis, J Clin Med,
doi:10.3390/jcm12072555Dimnjaković, Buble, Ivanko, Association of antidiabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy, Sci Rep,
doi:10.1038/s41598-024-57871-9Galindo, Dhatariya, Gomez-Peralta, Safety and efficacy of inpatient diabetes management with non-insulin agents: an overview of international practices, Curr Diabetes Rep,
doi:10.1007/s11892-022-01464-1Garg, Posa, Kumar, Diabetes and deaths of COVID-19 patients: systematic review of meta-analyses, Health Sci Rev (Oxf),
doi:10.1016/j.hsr.2023.100099Kosiborod, Esterline, Furtado, Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, doubleblind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol
Matthews, Herat, Schlaich, The impact of SGLT2 inhibitors in the heart and kidneys regardless of diabetes status, Int J Mol Sci,
doi:10.3390/ijms241814243Mcdonnell, Garg, Gopalakrishnan, Glycemic gap predicts mortality in a large multicenter cohort hospitalized with COVID-19, J Clin Endocrinol Metabol,
doi:10.1210/clinem/dgac587Nguyen, Ho, Nguyen, Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis, Metabolism
Permana, Yanto, Ht, Preadmission use of sodium-glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: a systematic review, meta-analysis, and metaregression, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2022.110205Reis, Silva, Silva, Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: the together randomized platform clinical trial, Lancet Reg Health Am,
doi:10.1016/j.lana.2021.100142Seisa, Saadi, Nayfeh, A systematic review supporting the endocrine society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures, J Clin Endocrinol Metabol,
doi:10.1210/clinem/dgac277Zhan, Weng, Qi, Effect of antidiabetic therapy on clinical outcomes of COVID-19 patients with type 2 diabetes: a systematic review and meta-analysis, Ann Pharmacother,
doi:10.1177/10600280221133577Zhu, She, Cheng, Association of blood glucose control and outcomes in patients with COVID-19 and preexisting type 2 diabetes, Cell Metabol
{ 'indexed': { 'date-parts': [[2024, 11, 30]],
'date-time': '2024-11-30T05:19:15Z',
'timestamp': 1732943955991,
'version': '3.30.0'},
'reference-count': 18,
'publisher': 'SAGE Publications',
'issue': '6',
'license': [ { 'start': { 'date-parts': [[2024, 11, 1]],
'date-time': '2024-11-01T00:00:00Z',
'timestamp': 1730419200000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by-nc/4.0/'}],
'content-domain': {'domain': ['journals.sagepub.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 11]]},
'abstract': '<jats:p> Our study evaluates the interconnection between diabetes treatment in the community '
'setting and diabetes treatment regimens in these patients during hospitalization. '
'</jats:p><jats:sec><jats:title>Methods</jats:title><jats:p> The patients were divided into '
'four groups according to blood glucose level during hospitalization. Group 1 included '
'patients with an average blood glucose ≤140\xa0mg/dl, Group 2 included patients with an '
'average blood glucose level between 140 and 180\xa0mg/dl, Group 3 included patients whose '
'blood glucose level was between 180 and 250\xa0mg/dl, and Group 4 included patients with '
'average blood glucose >250\xa0mg/dl. In all subjects, we assessed preadmission diabetes '
'treatment and prior diagnoses of major comorbidities (atherosclerotic cardiovascular disease, '
'congestive heart failure, chronic renal disease, chronic pulmonary diseases, and dementia. '
'</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Significant predictors '
'of mortality were the severity of COVID-19 (OR 62, CI 95%; 18–235, p < .000), acute renal '
'failure (OR 3.2, CI 95% - 1.26–8.2; p = .015), and a diagnosis of congestive heart failure '
'before hospitalization (OR 2.6; CI 95% 1.14–6.8; p = .024). Lower preadmission HbA1c levels, '
'insulin treatment in the hospital, SGLT-2 treatment before, and absence of acute renal '
'failure are significant predictors of good glycemic control during hospitalization. '
'</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> In patients with '
'type 2 diabetes hospitalized with COVID-19, poor long-term glycemic control is associated '
'with the level of hyperglycemia during hospitalization. </jats:p></jats:sec>',
'DOI': '10.1177/14791641241288390',
'type': 'journal-article',
'created': { 'date-parts': [[2024, 11, 29]],
'date-time': '2024-11-29T15:13:24Z',
'timestamp': 1732893204000},
'update-policy': 'http://dx.doi.org/10.1177/sage-journals-update-policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Impact of blood glucose control on clinical outcomes in type 2 diabetes patients hospitalized '
'with COVID-19 infection',
'prefix': '10.1177',
'volume': '21',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-9013-1271',
'authenticated-orcid': False,
'given': 'Elena',
'family': 'Chertok Shacham',
'sequence': 'first',
'affiliation': [{'name': 'Endocrinology, Emek Medical Center, Afula, Israel'}]},
{ 'given': 'Nimra',
'family': 'Maman',
'sequence': 'additional',
'affiliation': [{'name': 'Statistic and Science, Emek Medical Center, Afula, Israel'}]},
{ 'given': 'Avraham',
'family': 'Ishay',
'sequence': 'additional',
'affiliation': [{'name': 'Endocrinology, Emek Medical Center, Afula, Israel'}]}],
'member': '179',
'published-online': {'date-parts': [[2024, 11, 29]]},
'reference': [ { 'key': 'bibr1-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2022.44652'},
{ 'key': 'bibr2-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/jcm12072555'},
{ 'key': 'bibr3-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.cmet.2020.04.021'},
{ 'key': 'bibr4-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s11892-022-01464-1'},
{ 'key': 'bibr5-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1210/clinem/dgac277'},
{ 'key': 'bibr6-14791641241288390',
'unstructured': 'Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Clinical '
'spectrum of SARS-CoV-2 infection 2023; p 22. '
'https://www.covid19treatmentguidelines.nih.gov'},
{ 'key': 'bibr7-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1210/clinem/dgac587'},
{ 'key': 'bibr8-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1177/10600280221133577'},
{ 'key': 'bibr9-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/ijms241814243'},
{ 'key': 'bibr10-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S2213-8587(21)00180-7'},
{ 'key': 'bibr11-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2201662'},
{ 'key': 'bibr12-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.lana.2021.100142'},
{ 'key': 'bibr13-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.diabres.2022.110205'},
{ 'key': 'bibr14-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.metabol.2022.155196'},
{ 'key': 'bibr15-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.hsr.2023.100099'},
{ 'key': 'bibr16-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41598-024-57871-9'},
{ 'key': 'bibr17-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2021436'},
{ 'key': 'bibr18-14791641241288390',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2023.8516'}],
'container-title': 'Diabetes and Vascular Disease Research',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.sagepub.com/doi/pdf/10.1177/14791641241288390',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journals.sagepub.com/doi/full-xml/10.1177/14791641241288390',
'content-type': 'application/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journals.sagepub.com/doi/pdf/10.1177/14791641241288390',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 11, 29]],
'date-time': '2024-11-29T15:13:26Z',
'timestamp': 1732893206000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.sagepub.com/doi/10.1177/14791641241288390'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 11]]},
'references-count': 18,
'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2024, 11]]}},
'alternative-id': ['10.1177/14791641241288390'],
'URL': 'http://dx.doi.org/10.1177/14791641241288390',
'relation': {},
'ISSN': ['1479-1641', '1752-8984'],
'subject': [],
'container-title-short': 'Diabetes and Vascular Disease Research',
'published': {'date-parts': [[2024, 11]]}}
